HUTCHMED (China) HMDCF
NASDAQ HMDCF
$2.16 +0.00 (+0.00%)
At close: Sep 8, 2026 · 4:00 PM EDT

HUTCHMED (China) (HMDCF) Other Non-Current Liabilities (2015 - 2026)

HUTCHMED (China)'s (HMDCF) quarterly Other Non-Current Liabilities came in at $97.9 million in Q2 2026, up 5.2% year-over-year from $93.0 million in Q2 2025, and up 7.08% quarter-over-quarter from $91.4 million in Q4 2025.

Analysis

HUTCHMED (China) (HMDCF) Other Non-Current Liabilities (2015 - 2026) Analysis & Trends

HUTCHMED (China) (HMDCF) has reported Other Non-Current Liabilities for 12 consecutive years, with $97.9 million the latest figure, recorded in Q2 2026.

  • On a quarterly basis, Other Non-Current Liabilities rose 5.2% year-over-year to $97.9 million in Q2 2026; TTM through Jun 2026 was $97.9 million, a 5.2% increase from a year earlier, with the FY2025 full-year figure at $91.4 million, up 2066.72% from the prior year.
  • Other Non-Current Liabilities was $97.9 million for Q2 2026 at HUTCHMED (China), up from $91.4 million in the prior quarter.
  • Over five years, Other Non-Current Liabilities peaked at $97.9 million in Q2 2026 and troughed at $4.2 million in Q4 2024.
  • A 5-year average of $46.3 million and a median of $22.7 million in 2022 frame the typical range for Other Non-Current Liabilities.
  • Across the five-year window, Other Non-Current Liabilities slipped 4.53% in 2023 and surged 2066.72% in 2025, its largest moves.
  • Over 5 years, Other Non-Current Liabilities stood at $25.2 million in 2022, then dropped by 23.43% to $19.3 million in 2023, then plunged by 78.13% to $4.2 million in 2024, then surged by 2066.72% to $91.4 million in 2025, then climbed by 7.08% to $97.9 million in 2026.
  • The last three Other Non-Current Liabilities figures came in at $97.9 million (Q2 2026), $91.4 million (Q4 2025), and $93.0 million (Q2 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 211.50 Bn 197.51 Bn 7.24 Bn
2 Gilead Sciences 181.29 Bn 178.11 Bn 6.22 Bn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 82.55 Bn 74.56 Bn 3.93 Bn
5 Argenx Se 61.65 Bn 56.47 Bn 1.37 Bn
6 Moderna 54.65 Bn 49.52 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 34.18 Bn 30.87 Bn 992.69 Mn
8 Biogen 31.36 Bn 30.07 Bn 1.96 Bn
9 Roivant Sciences 30.01 Bn 30.01 Bn 1.16 Mn
10 HUTCHMED (China) 376.85 Mn 391.04 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 97.88 Mn
Dec 31, 2025 91.41 Mn
Jun 30, 2025 93.04 Mn
Dec 31, 2024 4.22 Mn
Jun 30, 2024 19.31 Mn
Jun 30, 2023 19.29 Mn
Dec 31, 2022 25.20 Mn
Jun 30, 2022 20.21 Mn
Dec 31, 2021 11.56 Mn
Jun 30, 2021 5.52 Mn
Mar 31, 2021 6.81 Mn
Dec 31, 2020 8.78 Mn
Jun 30, 2020 9.01 Mn
Dec 31, 2019 5.96 Mn
Sep 30, 2019 7.46 Mn
Jun 30, 2019 7.86 Mn
Mar 31, 2019 8.33 Mn
Dec 31, 2018 2.40 Mn
Jun 30, 2018 2.85 Mn
Dec 31, 2017 1.12 Mn